Richard J. Ulevitch, a Scientific Partner at Aravis, is Professor of Immunology and Chairman Emeritus of the Department of Immunology at the Scripps Research Institute, La Jolla CA. His research focuses on the basic mechanisms of the innate immune response and of acute and chronic injury resulting from inflammation. He is the author of more than 200 scientific publications.
Among his seminal discoveries are the identification and characterization of LPS Binding Protein, elucidation of the function of CD14 and its role in recognition of bacterial products such as LPS, discovery of p38 MAP kinase and identification of upstream and downstream components in the activation pathway. This work has provided the basis for multiple clinical trials including the use of anti-human CD14 monoclonal antibody therapy in sepsis and ARDS and the development of novel p38 inhibitors that are being tested in various settings of acute and chronic inflammation in man.
Dr. Ulevitch is currently a Venture Partner with 5AM Ventures (Palo Alto, CA and Waltham, MASS) and was a scientific advisor to the Lombard Odier Immunology Fund (1995 to 2005). He still maintains an active research laboratory supported by NIH funding.